OCBC Reports Rise in First-Quarter Net Profit, Makes S$1.4 Billion Offer for Insurance Arm
By Amanda Lee
Oversea-Chinese Banking Corp. said its first-quarter net profit rose mainly due to higher income from trading and fees and announced a 1.4 billion Singapore dollars (US$1.04 billion) privatization offer for its insurance arm.
Profit for the period ended March rose 5.0% on year to S$1.98 billion, with total income gaining 8.0% on year to S$3.63 billion, OCBC said Friday.
While net interest income rose 4% on year to S$2.44 billion, non-interest income was up 17% to S$1.19 billion.
During the first quarter, the bank's total allowances were S$169 million, up from S$110 million, mainly due to impairment charges.
"Our key markets in Asia are expected to be resilient, benefiting from increasing capital flows and supply chain diversification," the bank's Chief Executive Officer Helen Wong said.
She, however, warned of near-term risks due to geopolitical tensions.
Separately, OCBC said it was making a cash offer of S$25.60 a share to buy shares of Great Eastern Holdings that it doesn't already own. The offer is a 36.9% premium to Great Eastern's last traded price of S$18.70.
OCBC, which already owns a 88.44% stake in the insurance company, will finance the purchase through internal cash reserves.
Write to Amanda Lee at amanda.lee@wsj.com
(END) Dow Jones Newswires
May 09, 2024 20:55 ET (00:55 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks